Pfizer Inc (PFE) stock
Close on Nov 10, 2026Market cap $167.34BP/E 41.9Yield 5.86%
Pfizer Inc grew revenue 1.3% to $63.63B over the twelve months to Sep 27, 2026. Free cash flow was $11.79B, up 13.6% from a year earlier. At the latest close the market valued the company at $167.34B, 41.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 27, 2026
Valuation
- Market cap
- $167.34B
- P/E ratio
- 41.9
- Price to sales
- 2.63
- Price to book
- 1.88
- Dividend yield
- 5.86%
- Free cash flow yield
- 7.04%
Fundamentals
- Revenue
- $63.63B
- Net income
- $4.03B
- EPS, diluted
- $0.70
- Free cash flow
- $11.79B
- Book value per share
- $15.48
- Diluted shares
- 5.75B
Trading
- Next earnings
- Feb 2, 2027 (estimated, before the open)
- Previous close
- $29.23
- Open
- $29.17
- Day's range
- $28.95 – $29.38
- Volume
- 31,128,745
- Average volume (20 days)
- 36,321,449
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.44
- 52-week range
- $23.62 – $31.44
- RSI (14 days)
- 49.4
- Volatility (1 year)
- 22.0%
- Relative volume
- 0.86×
- WACC
- 6.6%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 10, 2026. The S&P 500 is measured by the SPY fund.
| Period | PFE | S&P 500 | Difference | PFE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.8% | -3.7% | +7.5 pts | ||
| 3 months | +8.5% | -2.7% | +11.3 pts | ||
| Year to date | +24.0% | +10.8% | +13.2 pts | ||
| 1 year | +26.6% | +11.2% | +15.4 pts | ||
| 3 years | +19.2% | +76.5% | −57.3 pts | +6.0% | +20.8% |
| 5 years | -22.6% | +72.9% | −95.6 pts | -5.0% | +11.6% |
| 10 years | +44.1% | +304.8% | −260.7 pts | +3.7% | +15.0% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pfizer filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About Pfizer
Pharmaceutical Preparations
The company operates in the biopharmaceutical sector through its Biopharma segment. It focuses on the discovery, development, licensing, and manufacturing of pharmaceutical therapies, vaccines, and healthcare treatments. Its portfolio and collaborative pipeline include products such as Comirnaty, Prevnar 13, Tukysa, Disitamab Vedotin, Zavzpret, Medrol, and Velsipity, serving patients, hospitals, and healthcare systems through commercial agreements and partnerships.
Company profile, executives and historyPfizer stock: common questions
What is Pfizer's stock price?
PFE closed at $29.36 on Nov 10, 2026, up 0.44% on the day. Over the past 52 weeks it traded between $23.62 and $31.44.
What is Pfizer's market cap?
Pfizer was worth $167.34B at the close on Nov 10, 2026: the share price times the diluted shares outstanding.
What is PFE's P/E ratio?
PFE trades at 41.9 times earnings, based on diluted earnings per share of $0.70 over the twelve months to Sep 27, 2026.
How much revenue does Pfizer make?
Pfizer reported revenue of $63.63B for the twelve months to Sep 27, 2026, up 1.3% from a year earlier.
Does Pfizer pay a dividend?
Yes. Pfizer paid $1.72 per share over the last twelve months, a yield of 5.86% at the latest price, and has raised its annual dividend 15 years in a row.
When does Pfizer report earnings next?
Pfizer is expected to report Q4 FY2026 results on Feb 2, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PFE stock performed over the past year?
Including dividends, PFE returned +26.6% over the past year, against +11.2% for the S&P 500.
How many PFE shares are sold short?
134M shares were sold short at the latest FINRA report, 2.36% of the float, or 4.6 days of average trading volume.
Who are Pfizer's competitors?
Companies most similar to Pfizer by business, industry and size include MRK, AZN, BMY, ABBV, LLY.
See a number that looks wrong?